Apr 16 |
INVO BioScience reports Q4 results
|
Apr 16 |
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
|
Jan 23 |
NAYA Biosciences to buy gene therapy company Florida Biotechnologies
|
Jan 23 |
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
|
Jan 17 |
INVO, NAYA announce new board members ahead of merger
|
Jan 17 |
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
|
Dec 11 |
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal
|
Dec 6 |
NAYA, ONK team up to evaluate potential cancer therapy combinations
|
Dec 6 |
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
|
Nov 28 |
INVO Bioscience regains compliance with Nasdaq rule
|